Dicerna Pharmaceuticals Inc. on Friday said it will pay Alnylam Pharmaceuticals Inc. $15 million plus stock to resolve litigation alleging misappropriated trade secrets and unfair business practices. http://bos.gl/yxTHS6l pic.twitter.com/mrpU8KDmmV
2:16 PM - 20 Apr 2018
0 replies
0 retweets
1 like
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.